Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [QUIET] · [HEALTH]
2 clusters · 4 sources · 7 days · First seen · Last updated
Multiple Sclerosis research and treatment developments
Overview
Research into Multiple Sclerosis (MS) has focused on both evaluating existing treatments and developing novel therapeutic mechanisms.
A real-world study of 447 adults with late-onset MS (LOMS) found that anti-CD20 therapies and sphingosine-1-phosphate (S1P) receptor modulators provided comparable clinical benefits. The study, utilizing MSBase registry data, reported no statistically significant differences in relapse rates or confirmed disability progression between the two groups.
Concurrently, new research is exploring methods to move beyond broad immune suppression. In Germany, scientists identified Complement factor H (CFH) as a potential protective mechanism that may prevent neuronal death by counteracting oxidative stress. Additionally, a collaborative study in Switzerland and Sweden has tested a therapy using red blood cells to induce immune tolerance. This approach aims to encourage the immune system to stop attacking healthy structures, with initial trials indicating the method is safe and well-tolerated.
Entities
University of Zurich · Karolinska Institute · University Medical Center Hamburg-Eppendorf · MSBase registry
Timeline
-
19 days ago
[HEALTH] 2 sourcesNew therapeutic approaches identified for Multiple SclerosisNew research offers hope for Multiple Sclerosis treatment through two distinct paths: using Complement factor H to protect neurons and employing red blood cell-based therapy to induce immune tolerance.
-
25 days ago
[HEALTH] 2 sourcesLate-onset MS treatments show comparable real-world outcomesA study of patients with late-onset multiple sclerosis found that anti-CD20 therapies and S1P receptor modulators offer comparable clinical benefits in managing relapse rates and disability progression.
Sources
acnr.co.uk · digitalcommons.library.tmc.edu · moneycab.com · www4.mdr.de